Clinical Trial Update: Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating blinatumomab in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen Research (Munich) GmbH | Conditions: B-ALL | Phase 2 | Status: COMPLETED | Results posted: 2015-01-07